首站-论文投稿智能助手
典型文献
NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma
文献摘要:
Multiple myeloma(MM)is still an incurable hematologic malignancy,which is eagerly to the discovery of novel therapeutic targets and methods.N-acetyltransferase 10(NAT10)is the first re-ported regulator of mRNA acetylation that is activated in many cancers.However,the function of NAT10 in MM remains unclear.We found significant upregulation of NAT10 in MM patients compared to normal plasma cells,which was also highly correlated with MM poor outcome.Further enforced NAT10 expression promoted MM growth in vitro and in vivo,while knockdown of NAT10 reversed those effects.The correlation analysis of acetylated RNA immunoprecipitation sequencing(acRIP-seq)and ribosome profiling sequencing(Ribo-seq)combined with RIP-PCR tests identified centrosomal protein 170(CEP170)as an important downstream target of NAT10.Interfering CEP170 expression in NAT10-OE cells attenuated the acceleration of cellular growth caused by elevated NAT 10.Moreover,CEP170 overexpression promoted cellular proliferation and chromosomal instability(CIN)in MM.Intriguingly,remodelin,a selective NAT 10 inhibitor,suppressed MM cellular growth,induced cellular apoptosis in vitro and prolonged the survival of 5TMM3VT mice in vivo.Collectively,our data indicate that NAT 10 acetylates CEP 170 mRNA to enhance CEP 170 translation efficiency,which suggests that NAT10 may serve as a promising therapeutic target in MM.
文献关键词:
作者姓名:
Rongfang Wei;Xing Cui;Jie Min;Zigen Lin;Yanyan Zhou;Mengjie Guo;Xiaojuan An;Hao Liu;Siegfried Janz;Chunyan Gu;Hongbo Wang;Ye Yang
作者机构:
Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Nanjing 210022,China;School of Medicine&Holistic Integrative Medicine,Nanjing University of Chinese Medicine,Nanjing 210023,China;Department of Hematology,Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250014,China;Division of Hematology and Oncology,Medical College of Wisconsin,Milwaukee,WI 53226,USA;School of Pharmacy,Key Laboratory of Molecular Pharmacology and Drug Evaluation(Yantai University),Ministry of Education,Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong,Yantai University,Yantai 264005,China;Bohai Rim Advanced Research Institute for Drug Discovery,Yantai 264003,China
引用格式:
[1]Rongfang Wei;Xing Cui;Jie Min;Zigen Lin;Yanyan Zhou;Mengjie Guo;Xiaojuan An;Hao Liu;Siegfried Janz;Chunyan Gu;Hongbo Wang;Ye Yang-.NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma)[J].药学学报(英文版),2022(08):3313-3325
A类:
acetylating,CEP170,acRIP,Ribo,centrosomal,Interfering,remodelin,5TMM3VT,acetylates
B类:
NAT10,promotes,proliferation,by,enhance,translation,efficiency,multiple,myeloma,Multiple,still,incurable,hematologic,malignancy,which,eagerly,discovery,novel,therapeutic,targets,methods,acetyltransferase,first,ported,regulator,acetylation,that,activated,many,cancers,However,function,remains,unclear,We,found,significant,upregulation,patients,compared,normal,plasma,cells,was,also,highly,correlated,poor,outcome,Further,enforced,promoted,growth,vitro,vivo,while,knockdown,reversed,those,effects,correlation,analysis,acetylated,immunoprecipitation,sequencing,ribosome,profiling,combined,tests,identified,protein,important,downstream,OE,attenuated,acceleration,cellular,caused,elevated,Moreover,overexpression,chromosomal,instability,CIN,Intriguingly,selective,inhibitor,suppressed,induced,apoptosis,prolonged,survival,mice,Collectively,our,data,indicate,suggests,may,serve,promising
AB值:
0.495931
相似文献
Globular adiponectin-mediated vascular remodeling by affecting the secretion of adventitial-derived tumor necrosis factor-αinduced by urotensin Ⅱ
Jun LI;Limin LUO;Yonggang ZHANG;Xiao DONG;Shuyi DANG;Xiaogang GUO;Wenhui DING-Department of Cardiology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Division of Cardiology,Department of Internal Medicine,Taihe Hospital,Hubei University of Medicine,Shiyan 442000,China;Division of Cardiology,Department of Internal Medicine,Peking University First Hospital,Beijing 100034,China;Department of Dermatology,the First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310003,China;Department of Cardiovascular Diseases,the Second Affiliated Hospital,Shantou University Medical College,Shantou 515041,China
N6?methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance
Xian Lin;Feng Wang;Jian Chen;Jing Liu;Yi?Bin Lin;Li Li;Chuan?Ben Chen;Qin Xu-Departments of Gynecology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Department of Radiation Oncology,Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,Fujian Medical University,Fuzhou 350014,China;Shenzhen Key Laboratory of Immunity and Inflammatory Diseases,Peking University Shenzhen Hospital,Shenzhen Peking University?the Hong Kong University of Science and Technology Medical Center,Shenzhen 518036,Guangdong,China;Outpatient Department,Fujian Hospital of People's Armed Police,Fujian Medical University,Fuzhou 350014,China
SNORA23 inhibits HCC tumorigenesis by impairing the 2?-O-ribose methylation level of 28S rRNA
Zhiyong Liu;Yanan Pang;Yin Jia;Qin Qin;Rui Wang;Wei Li;Jie Jing;Haidong Liu;Shanrong Liu-Department of Laboratory Diagnostics,Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Department of Gastroenterology and Hepatology,Zhongshan Hospital,Fudan University,Shanghai 200032,China;Department of Gastroenterology,Changhai Hospital,Second Military Medical University,Shanghai 200433,China;Shanghai Institute of Pancreatic Diseases,Shanghai 200433,China;Department of Chemistry and State Key Laboratory of Molecular Engineering of Polymers,Fudan University,Shanghai 200433 China;Department of General Surgery,Changzheng Hospital,Second Military Medical University,Shanghai 200433,China;Shanghai Fourth People's Hospital,Tongji University School of Medicine,Shanghai 200081,China
Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma
Jingrong Xian;Shiwen Wang;Yanyu Jiang;Lihui Li;Lili Cai;Ping Chen;Yue Liu;Xiaofei Zeng;Guoan Chen;Chen Ding;Robert M.Hoffman;Lijun Jia;Hu Zhao;Yanmei Zhang-Department of Laboratory Medicine,Huadong Hospital Affiliated to Fudan University,Shanghai 200040,China;Cancer Institute,Longhua Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 200032,China;Research Center on Aging and Medicine,Fudan University,Shanghai 200040,China;Shanghai Key Laboratory of Clinical Geriatric Medicine,Shanghai 200040,China;Department of Basic Science of Oncology,College of Basic Medical Sciences,Zhengzhou University,Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;School of Medicine,Southern University of Science and Technology,Shenzhen 518055,China;State Key Laboratory of Genetic Engineering,Human Phenome Institute,Institutes of Biomedical Sciences,School of Life Sciences,Zhongshan Hospital,Fudan University,Shanghai 200032,China;State Key Laboratory of Cell Differentiation and Regulation,Henan International Joint Laboratory of Pulmonary Fibrosis,Henan Center for Outstanding Overseas Scientists of Pulmonary Fibrosis,College of Life Science,Institute of Biomedical Science,Henan Normal University,Xinxiang 453007,China;Department of Surgery,University of California,San Diego 92101,USA;Anticancer Inc.,San Diego 92101,USA
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKK β
Zilu Zhang;Chenjing Ye;Jia Liu;Wenbin Xu;Chao Wu;Qing Yu;Xiaoguang Xu;Xinyi Zeng;Huizi Jin;Yingli Wu;Hua Yan-Shanghai Institute of Hematology,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;VIP Health Center,Affiliated Ruijin Hospital of Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs,School of Pharmacy,Shanghai Jiao Tong University,Shanghai 200240,China;Hongqiao International Institute of Medicine,Shanghai Tongren Hospital/Faculty of Basic Medicine,Chemical Biology Division of Shanghai Universities E-Institutes,Key Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
Nanoparticles targeting at methylases with high correlation to N6-methyladenosine-related lncRNA signatures as potential therapy of kidney clear cell carcinoma
Ruixuan Chen;Ping Ouyang;Licong Su;Xi Xu;Penghu Lian;Yanqin Li;Qi Gao;Yifan Zhang;Sheng Nie;Fan Luo;Ruqi Xu;Xiaodong Zhang;Xiaoxi Li;Yue Cao;Peiyan Gao;Juanjuan Kang;Jun Wu;Lu Li-National Clinical Research Center for Kidney Disease,State Key Laboratory of Organ Failure Research,Guangdong Provincial Clinical Research Center for Kidney Disease,Nanfang Hospital,Southern Medical University,Guangzhou 510000,China;Department of Health Management,Nanfang Hospital,Southern Medical University,Guangzhou 510000,China;Department of Hematology,Nanfang Hospital,Southern Medical University,Guangzhou 510000,China;Department of Urology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College(CAMS&PUMC),Beijing 100730,China;Department of Urology,Nanfang Hospital,Southern Medical University,Guangzhou 510000,China;Affiliated Foshan Maternity&Child Healthcare Hospital,Southern Medical University,Foshan 528000,China;School of Biomedical Engineering,Sun Yat-sen University,Shenzhen 518107,China;Department of Radiation Oncology,Nanfang Hospital,Southern Medical University,Guangzhou 510000,China
Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity
Zhang Weiwei;Yan Wenji;Qian Niansong;Han Quanli;Zhang Weitao;Dai Guanghai-Chinese People’s Liberation Army Medical School, Beijing 100853, China;Department of the Third Health Care, The Second Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The Hainan Medical Center, Chinese People’s Liberation Army General Hospital, Sanya 572022, China;Cancer Center, Beijing Tongren Hospital Affiliated to Capital Medical University, Economic and Technological Development Zone, Beijing 100176, China
Deubiquitinase ubiquitin-specific protease 3 (USP3) inhibits HIV-1 replication via promoting APOBEC3G (A3G) expression in both enzyme activity-dependent and -independent manners
Zhao Simin;Zheng Baisong;Wang Liuli;Cui Wenzhe;Jiang Chunlai;Li Zhuo;Gao Wenying;Zhang Wenyan-Center for Pathogen Biology and Infectious Diseases, Institute of Virology and AIDS Research, Key Laboratory of Organ Regeneration and Transplantation of The Ministry of Education, The First Hospital of Jilin University, Changchun, Jilin 130021, China;College of Life Science of Jilin University, Changchun, Jilin 130012, China;Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun, Jilin 130012, China;Jilin Provincial Key Laboratory on Molecular and Chemical Genetics, The Second Hospital of Jilin University, Changchun, Jilin 130041, China;Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130021, China
Stratifin promotes renal dysfunction in ischemic and nephrotoxic AKI mouse models via enhancing RIPK3-mediated necroptosis
Fang Wang;Jia-nan Wang;Xiao-yan He;Xiao-guo Suo;Chao Li;Wei-jian Ni;Yu-ting Cai;Yuan He;Xin-yun Fang;Yu-hang Dong;Tian Xing;Ya-ru Yang;Feng Zhang;Xiang Zhong;Hong-mei Zang;Ming-ming Liu;Jun Li;Xiao-ming Meng;Juan Jin-Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Institute of Innovative Drugs,School of Pharmacy,Anhui Medical University,The Key Laboratory of Anti-inflammatory of Immune Medicines,Ministry of Education,Hefei 230032,China;Department of Pharmacy,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Hospital of Stomatology,Anhui Medical University,Key Laboratory of Oral Diseases Research of Anhui Province,Hefei 230032,China;Department of Pharmacy,Changzheng Hospital,Naval Medical University,Shanghai 200003,China;Department of Nephrology,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China;School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China
KCNN4-mediated Ca2+/MET/AKT axis is promising for targeted therapy of pancreatic ductal adenocarcinoma
Xiao Mo;Cheng-fei Zhang;Ping Xu;Min Ding;Zhi-jie Ma;Qi Sun;Yu Liu;Hong-kai Bi;Xin Guo;Alaa Abdelatty;Chao Hu;Hao-jun Xu;Guo-ren Zhou;Yu-liang Jia;Hong-ping Xia-Sir Run Run Hospital,Nanjing Medical University,Nanjing 211166,China;School of Basic Medical Sciences&State Key Laboratory of Reproductive Medicine&Key Laboratory of Antibody Technique of National Health Commission&Jiangsu Antibody Drug Engineering Research Center,Nanjing Medical University,Nanjing 210092,China;Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research&The Affiliated Cancer Hospital of Nanjing Medical University,Nanjing 210092,China;Yijishan Hospital of Wannan Medical College,Wannan Medical College,Wuhu 241002,China
Pharmacodynamic,pharmacokinetic,and phase 1a study of bisthianostat,a novel histone deacetylase inhibitor,for the treatment of relapsed or refractory multiple myeloma
Yu-bo Zhou;Yang-ming Zhang;Hong-hui Huang;Li-jing Shen;Xiao-feng Han;Xiao-bei Hu;Song-da Yu;An-hui Gao;Li Sheng;Ming-bo Su;Xiao-li Wei;Yue Zhang;Yi-fan Zhang;Zhi-wei Gao;Xiao-yan Chen;Fa-jun Nan;Jia Li;Jian Hou-National Center for New Drug Screening,State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Yantai Key Laboratory of Nanomedicine&Advanced Preparations,Yantai Institute of Materia Medica,Yantai 264000,China;Department of Hematology,Renji Hospital,Shanghai Jiaotong University School of Medicine,Shanghai 200127,China;Shanghai Center for Drug Metabolism and Pharmacokinetics Research,Shanghai 201203,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。